Articles On Arc Exploration (ASX:ARX)

ASX health stocks fall 1.3% in past five days, while broader market is marginally up 0.7%  Neuren soars on sale of priority review voucher and $50 million share buyback Neurizon releases positive preclinical results on lead drug candidate...

Stockhead’s Sarah Hughan sits down with Aroa Biosurgery’s (ASX:ARX) founder and CEO Brian Ward to get the short end of the long story on the company’s latest news. The company’s biomaterial ECM technology aims to improve the rate and qualit...

  The ASX fell on new expectations for rate cuts All 11 ASX sectors fell, with real estate and healthcare hit hardest MinRes and Viva Energy dropped, Prodigy Gold rose 50pc   The ASX slid by 1.66% from near record highs in a broad sell-o...

Mixed revenue trends emerge from the latest batch of quarterly updates Proteomics plans to launch its predictive diabetes test next year Chimeric raises $5 million – but drops its daks to do so   As the end-of-October quarterly reporting...

Aroa looks to capitalise on growing US wound-care market forecast to reach US$13 billion by 2034 Company is continuing to expand clinical evidence supporting efficacy of its ECM products Growing prevalence of chronic conditions like diabe...

Stockhead’s health and biotech expert Tim Boreham is back in the studio for another instalment of the Health Kick Podcast. In this episode Tim chats with Brian Ward, founder and CEO at Aroa Biosurgery (ASX:ARX). Aroa was founded in 2008 by...

What is regenerative healing? Why are such healing products used? And where does AROA sits in the greater regenerative healing market? Aroa Biosurgery (ASX:ARX) founder and CEO Dr Brian Ward joins the Stockhead TV studio to investigate thes...

What is regenerative healing? Why are such healing products used? And where does AROA sits in the greater regenerative healing market? Aroa Biosurgery (ASX:ARX) founder and CEO Dr Brian Ward joins the Stockhead TV studio to investigate thes...

Given the strong potential returns on offer at the small end of the market, it could be worth adding a few small cap ASX stocks to a balanced investment portfolio if you have a high risk tolerance. But which small caps could be top options...

ASX 200 nears 8,000 points, boosted by mining stocks Monadelphous and Baby Bunting rose; Yancoal and Dexus fell RBA considered lifting rates in August, minutes revealed   The  S&P/ASX 200 index rose by 0.2% to finish near 8,000 points...

Aroa focused on expanding clinical evidence to support use of its ECM products in soft tissue repair Aroa expands Myriad Registry, the company’s largest prospective study to date Interim results of Symphony for complex non-healing diabetic...

ASX health stocks rise 0.8% past five days as broader market lifts 3.7%  Morgans says ProMedicus ‘produced yet another record result’ with net profit of $82.8m in FY24  CSL falls on FY24 results but Morgans still bullish on ASX’s largest h...

The 2024 Bioshares Biotech Summit being held in Fremantle from July 12-13 Morgans says conference likely to attract institutional and high net worth WA investors  Day one focus on new opportunities, finding the next blockbuster drug and re...

Looking for exposure to the healthcare sector in FY 2025? If you are, then check out the three ASX shares listed below. They have just been tipped as Bell Potter's top healthcare stocks to buy now: Aroa Biosurgery Ltd (ASX: ARX) Aroa Biosu...

If you're not averse to investing at the small side of the market, then it could be worth checking out Aroa Biosurgery Ltd (ASX: ARX). That's because analysts at Bell Potter believe the small cap ASX stock could rise materially from current...

AROA Biosurgery continues to expand its product line in regenerative tissue repair on back of positive clinical results Using ovine forestomach matrix, Aroa’s ECM technology offers top-tier regenerative performance at an attractive price p...

ASX health stock fall in past five days along with broader markets Sonic Healthcare cuts FY24 profit guidance, citing costs pressures and currency headwinds Aroa Biosurgery FY24 results in line with guidance with total revenue up 12% yoy...

Stockhead’s Sarah Hughan sits down with AROA Biosurgery (ASX:ARX) founder and CEO Brian Ward to get the short end of the long story on the company’s latest news. The soft-tissue regeneration company released its FY24 financial results with...

Tech stocks surged on ASX today, offset by losses in Mining stocks Gold and copper hit all-time highs Ethereum on the rise on rumours of ETF approvals in the US   The ASX 200 closed around -0.15% lower on Tuesday, as gains in Tech stocks...

Soft tissue repair company Aroa Biosurgery FY24 revenue grows 12% yoy to NZ$69.1 million Myriad revenue up 73% to NZ$23.3 million Aroa focused on delivering positive operating cashflows in FY25 Special Report: Soft tissue repair company...

Positive net cash inflows from operations of NZ$300k, exceed Q4 breakeven expectations Strong cash receipts from customers of NZ$18 million, reflect continued increase in Myriad and OviTex/OviTex PRS sales ARX reduces quarterly cash burn b...

The ASX inched higher on Tuesday ahead of the Fed’s rates call Lithium stocks flashed green today Amazon, CocaCola, Eli Lilly to report earnings later tonight   The ASX200 edged cautiously higher by +0.35% on Tuesday on the back of a Wall...

S&P/ASX 200 Health Care (ASX: XHJ) shares are up 0.44% on Tuesday while the ASX 200 is up 0.23%. But these three ASX healthcare shares are knocking it out of the park on this otherwise lacklustre day. Here's why. Paradigm Bio...

Aroa Biosurgery focuses on transitioning operations to cashflow positive in FY25 US distribution partner TELA Bio reports strong growth to flow through to Aroa Biotech making strong progress on clinical trials and new product lines Soft...

The ASX200 has ended Friday down 0.15pc, but ends week higher Property and Healthcare gains offset by Resources losses  Small Caps led by Gold50   Wall Street hit more record highs on Thursday in New York, the Australian market on Friday,...

Stockhead’s Ashtyn Hiron sits down with AROA Biosurgery (ASX:ARX) CEO Dr. Brian Ward to get the short end of the long story on the company’s latest news. Aroa Biosurgery’s Enivo system may reduce secondary complications in mastectomies, wit...

ASX health sector up in line with broader market but some names ail after quarterly results Cochlear lifts net profit guidance for FY24 after stronger than expected first half sales revenue  CSL to report half year results next week with b...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, that made announcements today.   ICYMI Leade...

AROA reports 80% increase in sales of high-margin Myriad in H1 FY24 TELA Bio’s sales of OviTex and OviTex PRS increase 37% during H1 FY24 on pcp Full-year FY24 guidance has been updated   Special Report: Aroa Biosurgery released strong...

Morgans releases its ASX wound care report seeing value in Aroa Biosurgery, Avita Medical and PolyNovo Global wound care market is estimated to grow at a CAGR of 5.9% to reach US$28.6 billion by 2028 ASX wound care companies head towards p...

Aroa Biosurgery maintains product revenue guidance for FY24, up 25-30% on FY23 Company’s US commercial operations perform particularly well during Q2 FY24 Myriad sales increase to 67% of company’s direct sales mix in Q2 from 50% in Q2 FY23...

ASX health stocks rise in past five days in line with broader markets Mach7 Technologies reports record quarterly sales orders for Q1 FY24 Aroa maintains FY24 revenue growth forecast at 30% after strong Q2 Healthcare and life sciences exp...

Aroa Biosurgery forecasts business growth of up to 30% annually with product revenue guidance of NZ$73-$76 million in FY24 New study highlights positive outcomes using Myriad Matrix and Myriad Morcells in complex traumatic wounds Aroa focu...

ASX health sector falls in line with broader markets on macroeconomic factors and global geopolitical tensions Health imaging stock Volpara announces fourth consecutive quarter of operating cashflow Several ASX healthcare names with positi...

ASX health sector fall in line with broader markets as macroeconomic factors create uncertainty Clinuvel down as its European label expansion of SCENESSE knocked back pending further data 2023 biotech market darling elevated to the S&P...

ASX health stocks fall 1.82% in the past five days in line as broader markets rise slightly Resmed sinks after delivering a mixed quarterly result including margins contracting Weight loss drug frenzy drives global big pharma plays Nova No...

ASX health stocks fall 2.4% in the past five days in line with broader markets Mesoblast crashes more than 50% after US FDA rejects a key product  ImpediMed falls after calls for board spill with discontent following cap raise Healthcare...

ASX health stocks up 1% in the past five days in line with broader markets Volpara records third quarter of positive cashflow following successful growth strategy Gut health a popular theme at 17th Bioshares Biotech Summit along with immun...

ASX health stocks outperforming the broader market but remain flattish for week Several ASX health plays undertaking capital raising with more expected in H2 CY23 Micro-X successfully tests its Argus bomb detection unit opening door to US$...

The S&P/ASX 200 Index (ASX: XJO) is having a tough time on Tuesday. In afternoon trade, the benchmark index is down 1.4% to 7,110.3 points. Four ASX shares that are falling more than most today are listed below. Here’s why they are...

Biotech Aroa has released its audited results for the 2023 financial year, hitting targets and achieving its expectations. The company looks ahead with a positive perspective on FY24, with the group providing new guidance today. The post A...

The market shows that biotechs are making a gradual comeback in 2023 What are some of the catalysts that will push this momentum further? ASX biotechs that announced FDA breakthroughs this year   After a challenging 2022, we are finally s...

ASX health stocks have fallen in the past five days in line with broader markets Volpara Health Technologies reports strong FY23 results, above Morgan’s expectations Pharmaxis reports positive trial results in potential breakthrough treatm...

There could be big returns lurking at the small end of town according to analysts at Morgans. Here’s what it is expecting from these small cap ASX healthcare shares: Aroa Biosurgery Ltd (ASX: ARX) The first small cap ASX healthcare share...

Pharmaxis widens clinical trial following FDA guidance Aroa receives US FDA 510K clearance Cynata gets Australian Ethics approval to commence Phase 2   Pharmaxis to widen Phase 2 trial after FDA feedback Fibrotic diseases specialist Pharm...

ASX health stocks rise 0.97% in the past five days in line with broader markets Impedimed up 99% after BIS tech named in latest US NCCN guidelines for lymphoedema  EBR Systems to release top line results at cardiac conference Heart Rhythm...

The health sector is seen by many experts as one that could remain resilient through times of economic distress. After all, people may cut out dining out or buying a new sofa, but they will still want to remain physically and mentally wel...

Several ASX health stocks are seeking US FDA approval for drugs/devices in the near future Telix Pharmaceuticals is chasing renal cancer imaging approval for TLX-250 CDx Aroa is awaiting an FDA decision on the required regulatory pathway...

ASX health stocks fall 1.75% for the past five days Several companies announce successful capital raises Healius drops 15% in the past five days as H1 FY23 results disappoint Healthcare and life sciences expert Scott Power, who has been a...

The All Ordinaries Index (ASX: XAO) is back in the green on Wednesday, driven higher by four shares leaping to new 52-week highs. Right now, the All Ordinaries Index is up 0.12%, trading at 7,606.9 points. Let’s take a closer look at fou...